UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/728,114	12/04/2003	Jugnu Jain-Pandey	VPI/02 135 US	7651
27916 7590 04/13/2011 VERTEX PHARMACEUTICALS INC.			EXAMINER	
130 WAVERL	Y STREET , MA 02139-4242		WEDDINGTON, KEVIN E	
CAMBRIDGE	, IVIA 02139-4242		VPI/02 135 US	PAPER NUMBER
			1614	
			NOTIFICATION DATE	DELIVERY MODE
			04/13/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

usptopatents@vrtx.com andrew_jackson@vrtx.com susan_batty-gunn@vrtx.com

<u>عا ، من</u>		Application No.	Applicant(s)		
Response to Rule 312 Communication		10/728,114	JAIN-PANDEY ET AL.		
		Examiner	Art Unit		
	The MAILING DATE of this communication a	appears on the cover shee	t with the correspondence address –		
1. ⊠ The _ a) ⊠	amendment filed on <u>02 March 2011</u> under 37 CFR entered.	1.312 has been considered	, and has been:		
b) 🗌	entered as directed to matters of form not affecting the scope of the invention.				
c) 🗌	disapproved because the amendment was filed after the payment of the issue fee. Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.				
d) 🗌	disapproved. See explanation below.		•		
e) 🗌	entered in part. See explanation below.				
		þ	ublishing Division		